Status:
NOT_YET_RECRUITING
Does The Addition Of Letrozole To Ultra-Long GnRH Agonists Help Adenomyosis Patients in ART? The AURA Trial
Lead Sponsor:
University of Palermo
Conditions:
Adenomyosis of Uterus
Infertility Assisted Reproductive Technology
Eligibility:
FEMALE
18-50 years
Phase:
PHASE4
Brief Summary
The AURA Trial seeks to improve fertility treatment for women affected by a condition known as adenomyosis. Adenomyosis often leads to heavy menstrual bleeding, pelvic pain, dyspareunia and can make i...
Eligibility Criteria
Inclusion
- \- Infertile patients affected by adenomyosis diagnosed by 2D-3D transvaginal ultrasound according to revised Morphological Uterus Sonographic Assessment consensus.
Exclusion
- concomitant uterine fibroids,
- Müllerian malformations,
- endometrial pathology,
- thin endometrium,
- hydrosalpinx,
- mucometra,
- previous surgery except for previous cesarean section,
- coagulation disorders,
- untreated endocrinopathies,
- severe seminal pathologies,
- double ET,
- ET different from the first one after adenomyosis treatment.
Key Trial Info
Start Date :
June 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
162 Patients enrolled
Trial Details
Trial ID
NCT06985186
Start Date
June 1 2025
End Date
December 1 2026
Last Update
May 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Bernabeu
Alicante, Alicante, Spain, 03016